Raiffeisen Bank International AG Has $1.87 Million Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Key Points

• Raiffeisen Bank International AG increased its position in Zimmer Biomet by 34.4% during Q1, bringing its total holdings to 16,659 shares valued at approximately $1.87 million.
• Zimmer Biomet's latest quarterly earnings showed an EPS of $1.81, exceeding analyst expectations and with revenue of $1.91 billion, marking a 1.1% increase from the previous year.
• The company announced a quarterly dividend of $0.24, providing an annualized dividend yield of 1.1% and a payout ratio of 21.24%.

Raiffeisen Bank International AG boosted its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 34.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 16,659 shares of the medical equipment provider's stock after acquiring an additional 4,268 shares during the quarter. Raiffeisen Bank International AG's holdings in Zimmer Biomet were worth $1,870,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Brighton Jones LLC acquired a new stake in shares of Zimmer Biomet during the 4th quarter valued at about $204,000. Alliancebernstein L.P. lifted its holdings in Zimmer Biomet by 7.5% in the 4th quarter. Alliancebernstein L.P. now owns 326,802 shares of the medical equipment provider's stock worth $34,520,000 after purchasing an additional 22,784 shares during the last quarter. Resona Asset Management Co. Ltd. bought a new position in Zimmer Biomet in the 4th quarter worth approximately $6,516,000. Aviva PLC increased its position in Zimmer Biomet by 103.7% in the 4th quarter. Aviva PLC now owns 122,774 shares of the medical equipment provider's stock worth $12,969,000 after buying an additional 62,507 shares during the period. Finally, Envestnet Asset Management Inc. increased its position in shares of Zimmer Biomet by 24.9% during the fourth quarter. Envestnet Asset Management Inc. now owns 250,194 shares of the medical equipment provider's stock valued at $26,428,000 after purchasing an additional 49,821 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ZBH has been the topic of a number of research reports. Raymond James Financial lowered their price objective on Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Evercore ISI decreased their price target on Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating on the stock in a research note on Tuesday, July 8th. Stifel Nicolaus set a $115.00 price target on Zimmer Biomet and gave the company a "buy" rating in a research note on Tuesday, May 6th. Robert W. Baird decreased their price target on Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. Finally, The Goldman Sachs Group decreased their price target on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 6th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $111.39.

Zimmer Biomet Stock Down 0.9%

ZBH stock traded down $0.84 during mid-day trading on Wednesday, reaching $91.21. The company had a trading volume of 2,094,135 shares, compared to its average volume of 1,792,570. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.44 and a quick ratio of 1.46. The stock has a 50 day simple moving average of $93.12 and a two-hundred day simple moving average of $100.01. The company has a market capitalization of $18.05 billion, a price-to-earnings ratio of 20.18, a PEG ratio of 2.15 and a beta of 0.68. Zimmer Biomet Holdings, Inc. has a 52 week low of $89.22 and a 52 week high of $116.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $1.91 billion during the quarter, compared to analysts' expectations of $1.89 billion. Zimmer Biomet had a return on equity of 12.73% and a net margin of 11.86%. The business's revenue was up 1.1% on a year-over-year basis. During the same period last year, the firm posted $1.94 earnings per share. As a group, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, July 31st. Investors of record on Thursday, June 26th were given a dividend of $0.24 per share. The ex-dividend date was Thursday, June 26th. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. Zimmer Biomet's payout ratio is currently 21.24%.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of Zimmer Biomet stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the transaction, the insider directly owned 20,424 shares of the company's stock, valued at approximately $1,940,280. The trade was a 4.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.39% of the stock is owned by corporate insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.